Stratec (SBS) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Business model and market positioning

• Leading OEM provider of automated solutions for diagnostics and translational research, with a unique model focused on development and manufacturing for partners and a global installed base in high-complexity IVD segments.

• Maintains long-term contracts and partnerships, managing products through their entire lifecycle, including obsolescence and recurring revenue streams from consumables and service parts.

• Installed base includes 15,000 medium/high-throughput and 40,000 low-throughput analyzers, with a strong presence in molecular, immunoassay, and hematology markets.

• Flexible outsourcing model enables collaboration with most top 20 diagnostic companies and innovation leaders, leveraging technology and regulatory expertise.

• Focus on operational excellence, technology leadership, and expanding footprint in the US and Asia-Pacific, with realized sales synergies from the Natech acquisition.

Revenue trends and financial performance

• Revenue split is shifting, with development revenues expected to remain at 15–20% and service/consumables at 37%.

• 2023 and 2024 are forecasted as flat years after strong COVID-19-driven growth; 22% revenue growth from 2019 to 2023 (CAGR >4%).

• Sales for 9M 2024 declined 6.0% year-over-year to €176.3 million, mainly due to lower demand for molecular diagnostics and postponed deliveries.

• Adjusted EBIT margin for 2024 expected at 10–12%, with a goal to return to pre-COVID historical margins (~15%) as market rebounds; 9M 2024 margin was 8.4%.

• Free cash flow improved to €13.0 million for 9M 2024, with Q4 2024 operational cash flow over €40 million and free cash flow €25 million.

Industry trends and strategic focus

• Outsourcing is increasing due to high investment and regulatory complexity; the company manages regulatory compliance for partners.

• Product lifecycles are lengthening, requiring significant obsolescence management and ongoing development.

• Growth areas include smart consumables, advanced imaging, high-sensitivity immunoassays, and cell & gene therapy, with AI-enabled workflows and software as differentiators.

• Partnerships with innovation leaders and top IVD companies ensure access to emerging technologies and future market relevance.

• M&A remains a focus, with recent US expansion via the Natech acquisition supporting complex consumables growth.